Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), executed a round of stock transactions during the first week of March 2026 that combined sales and option exercises.
Between March 3 and March 5, 2026, Rubinstein sold a total of 92,823 shares of the company’s common stock in transactions that amounted to approximately $1.49 million. The reported sale prices ranged between $15.49 and $16.60 per share. At the time of reporting, Adaptive Biotechnologies was trading at $15.93, representing a 105% increase over the prior 12 months. InvestingPro analysis cited in company reporting indicates the shares may be trading above InvestingPro’s Fair Value estimate.
In parallel with those sales, Rubinstein exercised stock options on March 3, 4, and 5 to acquire a combined total of 73,610 shares of Adaptive Biotechnologies common stock. The option exercises were at strike prices of $6.55 and $12.14, and the aggregate value of the exercised options was reported as $721,993.
The Form 4 filing for these transactions notes that the reported sales were carried out pursuant to a Rule 10b5-1 trading plan the reporting person adopted on November 18, 2025. The filing documents the timing and mechanics of the trades as part of that pre-established plan.
Separately, Adaptive Biotechnologies released fourth-quarter 2025 financial results that outperformed analyst projections. The company posted an earnings per share (EPS) of -$0.09, a 50% positive surprise compared with the consensus forecast of -$0.18. Revenue also topped expectations, coming in at $71.7 million versus an anticipated $59.33 million.
Following the earnings release, two sell-side firms adjusted their price targets. TD Cowen raised its target to $21 while keeping its prior rating in place. BTIG increased its price target to $22, citing robust growth in Adaptive Biotechnologies’ core Minimal Residual Disease (MRD) business. The MRD segment expanded by 54% year over year in the fourth quarter and grew 46% for the full year, according to the company’s reported figures.
The company is included among the more than 1,400 U.S. equities covered by InvestingPro’s Pro Research Reports, which provide additional metrics and ProTips for subscribers. The Form 4 and earnings disclosures together provide a snapshot of recent insider activity and operational performance at Adaptive Biotechnologies without offering guidance on future share movement.
Disclosure: